Screener
Harrow HROW IHEEZO — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Harrow in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Harrow’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001493152-26-022254
| Line item | For the Three Months Ended March 31, 2026 | For the Three Months Ended March 31, 2025 |
|---|---|---|
| IHEEZO | $1,851,000 | $5,222,000 |
| VEVYE | 20,947,000 | 21,516,000 |
| Other branded products | 7,833,000 | 956,000 |
| Other revenues | 73,000 | 86,000 |
| Branded revenue, net | 30,704,000 | 27,780,000 |
| Compounding revenue, net | 13,499,000 | 20,051,000 |
| Total revenues, net | $44,203,000 | $47,831,000 |
Item 1. Financial Statements (unaudited) Item
FAQ
- What is Harrow's IHEEZO — revenue?
- Harrow (HROW) reported IHEEZO — revenue of $1.85M in Q1 2026.
- How has Harrow's IHEEZO — revenue changed year-over-year?
- Harrow's IHEEZO — revenue decreased by 64.6% year-over-year, from $5.22M to $1.85M.
- What does IHEEZO — revenue mean?
- This metric represents the total gross revenue generated from the sale of a specific pharmaceutical product or service line, net of any assessed taxes. It serves as a primary indicator of market adoption and commercial success for the product within the company's portfolio. Tracking this figure allows investors to evaluate the growth trajectory and revenue contribution of the specific segment relative to the company's overall financial performance.
Ask your AI about Harrow's iheezo — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude